Regeneron Pharmaceuticals, Inc. (REGN)
NASDAQ: REGN · Real-Time Price · USD
603.58
-2.03 (-0.34%)
May 5, 2025, 4:00 PM EDT - Market closed
Regeneron Pharmaceuticals Revenue
Regeneron Pharmaceuticals had revenue of $3.03B in the quarter ending March 31, 2025, a decrease of -3.70%. This brings the company's revenue in the last twelve months to $14.09B, up 7.52% year-over-year. In the year 2024, Regeneron Pharmaceuticals had annual revenue of $14.20B with 8.27% growth.
Revenue (ttm)
$14.09B
Revenue Growth
+7.52%
P/S Ratio
4.61
Revenue / Employee
$932,457
Employees
15,106
Market Cap
63.78B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 14.20B | 1.08B | 8.27% |
Dec 31, 2023 | 13.12B | 944.30M | 7.76% |
Dec 31, 2022 | 12.17B | -3.90B | -24.26% |
Dec 31, 2021 | 16.07B | 7.57B | 89.14% |
Dec 31, 2020 | 8.50B | 1.94B | 29.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
AstraZeneca | 54.98B |
Novartis AG | 53.22B |
Eli Lilly and Company | 49.00B |
Thermo Fisher Scientific | 42.90B |
REGN News
- 4 days ago - Regeneron to Highlight Advances at ASCO with Phase 3 Adjuvant Libtayo® (cemiplimab) CSCC Updates and Promising Early Blood Cancer Data with Linvoseltamab Combination - GlobeNewsWire
- 4 days ago - Dupixent® (dupilumab) Data Presented at ATS Reinforce Impact of Targeting Key Type 2 Inflammation Drivers to Improve Outcomes for Chronic Respiratory Diseases - GlobeNewsWire
- 6 days ago - Regeneron Pharma Margins Tighten As Competition Grows, Stock Slides - Benzinga
- 6 days ago - Regeneron Pharmaceuticals, Inc. (REGN) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 6 days ago - Top Stock Movers Now: Honeywell, Sherwin-Williams, Regeneron, and More - Investopedia
- 6 days ago - Regeneron Stock Plummets After Earnings Miss - Barrons
- 6 days ago - Regeneron Pharma's first-quarter results miss on lower Eylea demand - Reuters
- 6 days ago - Regeneron Reports First Quarter 2025 Financial and Operating Results - GlobeNewsWire